Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect on emraclidine PK in healthy adults
NCT05915546Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of emraclidine in schizophrenia (2 arms), sponsored by Cerevel Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Plasma Concentration and 2 more. Started Jun 2023; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05915546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05915546.